Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| June 3, 2022 | $0.30 | 2022-05-24 | 2022-05-25 |
| March 10, 2022 | $0.30 | 2022-02-28 | 2022-03-01 |
| June 3, 2021 | $0.30 | 2021-05-24 | 2021-05-25 |
| December 12, 2019 | $0.25 | 2019-12-02 | 2019-12-03 |
| January 24, 2019 | $0.25 | 2019-01-09 | 2019-01-10 |
Dividends Summary
- Consistent Payer: has rewarded shareholders with 6 dividend payments over the past 4 years.
- Total Returned Value: Investors who held PRPH shares during this period received a total of $2.40 per share in dividend income.
- Latest Payout: The most recent dividend of $0.30/share was paid 1330 days ago, on June 3, 2022.
- Dividend Growth: Since 2018, the dividend payout has decreased by 70.0%, from $1.00 to $0.30.
- Dividend Reliability: PRPH has maintained or increased its dividend for 5 consecutive payments.
Company News
ProPhase Labs reported that over $3.3 million of its $3.8 million convertible debt has been converted into equity, reducing liabilities and strengthening the balance sheet. The company attributes recent stock price volatility to technical factors including debt conversions, a reverse stock split, and transition to OTC markets rather than changes ...
ProPhase Labs reported a Q2 2025 revenue of $1.2 million, missing analyst expectations, but narrowed its GAAP loss to $(0.11) per share. The company is focusing on cost reduction, potential insurance receivables recovery, and exploring a sale of its Nebula Genomics division.
ProPhase Labs announced the formation of a Clinical Science Advisory Board to support the commercialization of its BE-Smart molecular test for esophageal disease. The advisory board includes experts in the field and aims to accelerate the regulatory and commercialization pathway for the test.
ProPhase Labs, Inc. (NASDAQ: PRPH) announced the pricing of its underwritten public offering of 4,170,000 shares of common stock at $0.72 per share, raising approximately $3 million. The company plans to use the net proceeds for working capital and general corporate purposes.
The antibody production market is expected to grow significantly due to the increasing demand for targeted therapies and advancements in biotechnology, such as recombinant DNA technology and high-throughput screening methods.
